Timberlyne Therapeutics Headquarters & Office Locations

Timberlyne Therapeutics is headquartered in San Diego, California, United States. Founded in 2024, the company employs approximately 13 people worldwide.

Where is Timberlyne Therapeutics's main office?

Timberlyne Therapeutics's main headquarters office is located at San Diego, California 92134, United States. This is the company's primary corporate address.

What does Timberlyne Therapeutics do?

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for autoimmune diseases. We are leveraging the extensive drug development expertise of our team to acquire best-in-class assets against compelling targets, and applying them to disease areas with significant unmet need. Timberlyne’s lead program, CM313, is an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38. By targeting CD38, highly expressed on plasma cells, NK cells, and other immune cells, CM313 can modulate multiple arms of the immune system leading to both rapid and durable responses across a range of autoimmune diseases. CM313 has been tested in numerous disease states including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma. Timberlyne plans to develop CM313 across a broad range of autoimmune indications. Launched in 2024, Timberlyne has raised $180 million from leading life sciences investors.